OBJECTIVES: As novel treatments for type II diabetes enter the market, there is a need to assess their long-term clinical and economic outcomes compared to current treatments. These comparisons can assist decision-makers in determining the appropriate place in therapy. Our objective was to review the existing pharmacoeconomic literature evaluating the cost-effectiveness and overall costs of treatment associated with liraglutide in type II diabetes.   METHODS: We identified English-language cost-effectiveness, cost-utility or cost analyses that compared liraglutide to one or more anti-diabetic agents via MEDLINE and EMBASE through March 1, 2013. Full text articles meeting the inclusion criteria were retrieved and information on the study design and results were abstracted. Costs were converted to 2012 US dollars in order to facilitate comparisons across studies. RESULTS: A total of 3 cost comparison studies and 6 cost-utility studies were identified for inclusion. Across cost comparison studies, liraglutide treatment resulted in cost savings ranging from $1,075 to $1,298 (1.2 mg) and $1,162 to $2,147 (1.8 mg) over a 10 year time horizon. Cost-utility analysis results reported base case ICERs ranging from $15,774 to $40,128/QALY for liraglutide 1.2 mg and $8,497 to $66,031/QALY for liraglutide 1.8 mg. Estimates were most sensitive to variations in time horizon and cardiovascular complication rates. Based on often cited cost-utility thresholds, liraglutide was determined to have a probability of being cost effective between 58% (liraglutide 1.8 mg vs. sitagliptin 100 mg) and 93% (liraglutide 1.2 mg vs. glimepiride 4 mg). CONCLUSIONS: Liraglutide appears to be a cost-effective adjunct treatment for type II diabetes and may also be associated with a reduction in diabetes-related complication costs; however, ICER values are largely dependent on the duration of liraglutide treatment benefit and the time horizon of the analysis.